down arrow

Lepu Biopharma Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100004SM4
HKD
5.34
-0.06 (-1.11%)

Dec 12

HKG

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
SciClone Pharmaceuticals (Holdings) Ltd.
Beijing Tong Ren Tang Chinese Medicine Co., Ltd.
Livzon Pharmaceutical Group, Inc.
Luye Pharma Group Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Pharmaceuticals Holding Co., Ltd.
Shandong Boan Biotechnology Co., Ltd.
RemeGen Co., Ltd.
Everest Medicines Ltd.
InnoCare Pharma Ltd.
Lepu Biopharma Co., Ltd.
Why is Lepu Biopharma Co., Ltd. ?
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
  • Poor long term growth as Net Sales has grown by an annual rate of 6.34% and Operating profit at 12.64% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 93.48%, its profits have risen by 26.6%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Lepu Biopharma Co., Ltd. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Lepu Biopharma Co., Ltd.
93.48%
0.27
83.45%
Hang Seng Hong Kong
27.36%
1.06
25.88%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
6.34%
EBIT Growth (5y)
12.64%
EBIT to Interest (avg)
-2.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.52
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
19.22
EV to EBIT
-6562.55
EV to EBITDA
-7104.01
EV to Capital Employed
13.01
EV to Sales
14764.26
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.20%
ROE (Latest)
-0.22%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Icon
Not enough Data to analyse Financial Trend
Icon
Not enough Data to analyse Financial Trend
Here's what is working for Lepu Biopharma Co., Ltd.
Net Sales
At HKD 254.4 MM has Grown at 227.98%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely positive

Net Sales (HKD MM)

Inventory Turnover Ratio
Highest at 6.7% and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Net Sales
Highest at HKD 254.4 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (HKD MM)

Raw Material Cost
Fallen by -122.67% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
At HKD 57.54 MM has Grown at 12.66%
period on period (QoQ)
MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Lepu Biopharma Co., Ltd.
Net Profit
At HKD -243.16 MM has Fallen at -501.31%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (HKD MM)

Interest
Highest at HKD 15.75 MM
in the last five periods and Increased by 71.72% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)

Cash and Eqv
Lowest at HKD 494.77 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio
Highest at 53.39 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."